LI YIWEN,LUDWIG DALE LINCOLN,MOLKENTHIN VERA,SHEN JUQUN,SNAVELY MARSHALL DAVENPORT
申请号：
IN201817004758
公开号：
IN201817004758A
申请日:
2018.02.08
申请国别(地区):
IN
年份:
2018
代理人:
摘要：
The present disclosure relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1 ), useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics. Said antibodies have specific variable chain sequences. According to the experimental results, they demonstrate superior association rates that translate into better in vivo activity and T cell response to a tumor cells.
